HOLD with $225 stop, protective puts, and trim into relief bounces; wait for structural confirmation (higher low in price, higher low in RSI, close above 20 SMA on rising volume) before scaling in

• Death cross cannot be dismissed for 'cash compounders' — price action matters regardless of fundamentals
• E. coli September 2026 incident remains unresolved overhang with asymmetric downside risk
• Q2 strength is already priced in; market is pricing forward expectations including Q3/Q4 risk
• Q3 earnings in early November is a binary catalyst — fighting unknown overhangs before resolution is uncompensated risk
• Buybacks of $856 million are rounding error against 30% market decline; management historically poor at timing own stock
• RSI at 24.89 indicates trending market (lower lows together), not bottoming pattern
• MACD histogram being barely negative means decelerating selling pressure, not exhaustion — not a directional signal
• Bollinger band below lower band allows 'band walks' persisting for weeks/months, not a buy signal
• 10-year yield at 26-year high compresses present value of MCD's long-duration cash flows
• Downside scenario: $195 (-15% from current levels) if bad Q3 print and E. coli escalation
• Upside scenario: $265 (+15% from current levels) if clean Q3 print and E. coli resolution
• Risk asymmetry: if stopped out at $225 after scaling in at $230, portfolio loses 6% (3x conviction position × 2% stop)
• $4.24 average daily range makes $5 stop buffer inadequate — will get stopped out before any reversal
• HOLD captures 3.32% dividend carry while preserving optionality for clearer signals
• Aggressive analyst conflates 'missing upside' with risk — permanent capital loss is the actual risk to manage

→ vs aggressive: Death cross argument: dismissing it for quality franchises is 'faith-based investing' with poor macro track record

→ vs aggressive: E. coli resolution: 'weeks not quarters' claim has no supporting information; Chipotle pattern shows food safety events can damage comps for 2-3 quarters

→ vs aggressive: Q2 strength: already in the price; aggressive analyst ignoring 7% sequential revenue decline in Q1 and forward risk

→ vs aggressive: Buyback signal: $856 million is rounding error; management historically terrible at timing own stock

→ vs aggressive: Technical 'bottom' signals: RSI 24.89 is not exhaustion (no higher low divergence), MACD barely negative is not directional, Bollinger band breaks can walk lower for months

→ vs aggressive: Yield argument: Polymarket 96% no-cut probability ignores absolute yield level effect on long-duration assets; recession scenario that would lower yields would also crush consumer comps

→ vs aggressive: Scaling strategy: $5 stop below $230 entry against $4.24 daily range will trigger on pattern and noise, not signal

→ vs aggressive: HOLD as 'floor not ceiling': disagreement — HOLD with defined stops and protective puts is the right posture, not aggressive scaling

HOLD with defined risk - maintain current exposure, capture the 3.32% dividend, do not initiate new positions without confirmation (RSI bullish divergence plus close above 20 SMA on rising volume), use protective puts for asymmetric hedge, trim 25-33% into relief bounce toward $241-250

• Neither bull nor bear case is decisive; both sides are anchored to their priors
• Stock at $230, down 31% from February high, trading at 16.75x forward P/E with 46.5% operating margins and 3.32% dividend yield
• Death cross technical picture is a real headwind: 19% below 200 SMA, 10% below 50 SMA, RSI at 24.89, no bullish divergence, MACD negative
• E. coli situation is an unresolved overhang - resolution timeline cannot be asserted with confidence
• Q2 results showed fundamentally sound business with $6.26 billion in annual free cash flow
• Q3 earnings is the binary catalyst that justifies a directional shift
• Protective puts at $215-220 strikes provide asymmetric downside protection while preserving dividend carry
• Trim 25-33% of position into relief bounce toward $241-250 - most underappreciated tactical element
• Wait for confirmed technical reversal or clean Q3 print before adding aggressively
• Aggressive analyst's thesis-driven stubbornness on technicals is dangerous; conservative analyst overstating 'permanent loss of capital' as 15% drawdown scenario

→ vs aggressive: Thesis-driven stubbornness on technicals - cannot dismiss death cross, RSI at 24.89, MACD negative, and 7-month lower highs/lower lows as lagging noise

→ vs aggressive: Overconfident E. coli resolution timeline - 'weeks not quarters' is an assertion without evidence; Chipotle comparison dismissed too readily

→ vs aggressive: Misinterpreting buyback acceleration as insider signal - $856M is rounding error against selling pressure and consistent with decade-long policy

→ vs aggressive: Framing risk as 'missing upside' is marketing copy, not analysis - permanent bullish bias masquerading as risk management

→ vs conservative: 'Permanent loss of capital' framing is dramatic - scenario is 15% drawdown, not wipeout; MCD generates $6.26B FCF and 3.32% dividend is secure

→ vs conservative: Being too dismissive of deep value setup - 16.75x forward P/E with 46.5% operating margins on high-quality compounder has merit

→ vs conservative: Attack on $5 stop buffer is mathematically unfair - conflating $4.24 daily range with sustained drawdown; proper position sizing makes $5 stop reasonable

→ vs conservative: 'HOLD with $225 stop' is still a long position with real downside risk - framing it as 'disciplined sideline' is pretentious; still making directional bet